Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

• Status: Completed
• Trial end date: 2004-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents (hormones that stimulate the bone marrow to make more red blood cells).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Watson Pharmaceuticals
• Treatments: Ferric Compounds; Ferric gluconate; Iron

Criteria

Inclusion Criteria:

• Moderate to severe anemia

• Iron deficiency

• Moderate to severe chronic kidney disease

Exclusion Criteria:

• Receiving dialysis

• Known sensitivity to Ferrlecit® or any of its components

• Receiving therapy with erythropoietic agent

• Clinically unstable